Sarepta's Stock Rises on Positive Updates on DM1 Therapy

Impact · against what's priced in

Sarepta Therapeutics sees a positive catalyst as safety committee approval for SRP-1003 reduces clinical risk and establishes an early 2026 readout timeline. Arrowhead Pharmaceuticals benefits from the validation of a $200 million milestone payment, while competitors Avidity and PepGen face relative devaluation due to their own comparative safety hurdles in the DM1 space.

SRPT+0.60: No priced-in read yet

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

What matters in this story

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

What matters in this story

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

How each ticker is affected

Connected tickers

Track these names every morning.

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

What matters in this story

Next reads from the same story arc

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

Sarepta's Stock Rises on Positive Updates on DM1 Therapy

What matters in this story

Next reads from the same story arc

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

How each ticker is affected

Connected tickers

Track these names every morning.

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT